Abstract:Background and purpose A recent paradigm shift in proarrhythmic risk assessment suggests that the integration of clinical, non-clinical, and computational evidence can be used to reach a comprehensive understanding of the proarrhythmic potential of drug candidates. While current computational methodologies focus on predicting the incidence of proarrhythmic events after drug administration, the objective of this study is to predict concentration-response relationships of QTc as a clinical endpoint. Experimental approach Full heart computational models reproducing human cardiac populations were created to predict the concentration-response relationship of changes in the QT interval as recommended for clinical trials. The concentration-response relationship of the QT-interval prolongation obtained from the computational cardiac population was compared against the relationship from clinical trial data for a set of well-characterized compounds: moxifloxacin, dofetilide, verapamil, and ondansetron. Key results Computationally derived concentration–response relationships of QT interval changes for three of the four drugs had slopes within the confidence interval of clinical trials (dofetilide, moxifloxacin and verapamil) when compared to placebo-corrected concentration-ΔQT and concentration-ΔQT regressions. Moxifloxacin showed a higher intercept, outside the confidence interval of the clinical data, demonstrating that in this example, the standard linear regression does not appropriately capture the concentration-response reulsts at very low concentrations. The concentrations corresponding to a mean QTc prolongation of 10 ms were consistently lower in the computational model than in clinical data. The critical concentration varied within an approximate ratio of 0.5 (moxifloxacin and ondansetron) and 1 times (dofetilide, verapamil) the critical concentration observed in human clinical trials. Notably, no other in silico methodology can approximate the human critical concentration values for a QT interval prolongation of 10 ms. Conclusion and implications Computational concentration-response modelling of a virtual population of high-resolution, 3-dimensional cardiac models can provide comparable information to clinical data and could be used to complement pre-clinical and clinical safety packages. It provides access to an unlimited exposure range to support trial design and can improve the understanding of pre-clinical-clinical translation.

The virtual assay software for human in silico drug trials to augment drug cardiac testing

Cross clinical-experimental-computational qualification of in silico drug trials on human cardiac purkinje cells for proarrhythmia risk prediction

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Virtual clinical QT exposure-response studies – A translational computational approach

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Real-time prediction of drug-induced proarrhythmic risk with sex-specific cardiac emulators

Cardiovascular disease models: A game changing paradigm in drug discovery and screening

Replicating clinical placebo effects in computational trials: Bridging the gap between in silico and clinical studies

Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform

Advanced Cardiovascular Toxicity Screening: Integrating Human iPSC-Derived Cardiomyocytes with In Silico Models

Digital Twinning of the Human Ventricular Activation Sequence to Clinical 12-lead ECGs and Magnetic Resonance Imaging Using Realistic Purkinje Networks for in Silico Clinical Trials

Cardiac Digital Twin Pipeline for Virtual Therapy Evaluation

SILICOFCM platform, multiscale modeling of left ventricle from echocardiographic images and drug influence for cardiomyopathy disease

High-Throughput Assessment Of Drug Cardiac Safety Using A High-Speed Impedance Detection Technology-Based Heart-On-A-Chip

Drug discovery through functional screening in the Drosophila heart

Clinical trials in-a-dish for cardiovascular medicine

Enhanced drug classification using machine learning with multiplexed cardiac contractility assays

GPU accelerated digital twins of the human heart open new routes for cardiovascular research

In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment

Cardiomyocyte electrical-mechanical synchronized model for high-content, dose-quantitative and time-dependent drug assessment

Combined Effects of Electric Stimulation and Microgrooves in Cardiac Tissue‐on‐a‐Chip for Drug Screening